In addition, FGF23 suppression by the calcimimetic etelcalcetide inhibited progression of left ventricular hypertrophy in patients on hemodialysis, also supporting a direct pro-hypertrophic action of FGF2341. The gene discussed is FGF23; the disease is left ventricular hypertrophy.